Shaker A Mousa
Shaker A Mousa
Various integrin antagonist candidates, including antibodies, cyclic peptides, peptidomimetics and non-peptides, have been clinically evaluated and have been shown to successfully modulate certain disease processes. The most advanced integr...
Oxygen carriers [0.03%]
氧载体
Thomas M S Chang
Thomas M S Chang
Three polyhemoglobins, formed by intermolecular cross-linking of hemoglobin molecules are in advanced phase III clinical trials and two conjugated hemoglobins, formed by cross-linking of hemoglobin molecules with soluble polymer, are also u...
Shaker A Mousa
Shaker A Mousa
Despite efforts in finding and developing new anticoagulants, unfractionated heparin and low molecular weight heparin (LMWH) will continue to play a pivotal role in the management of thrombotic disorders. While bleeding and heparin-induced ...
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia [0.03%]
治疗肝素诱导的血小板减少症的抗凝药物
Walter P Jeske,Jeanine M Walenga
Walter P Jeske
Because patients with heparin-induced thrombocytopenia (HIT) have an extremely high frequency of developing thrombosis, treatment options other than heparin are essential. Prophylaxis against thrombosis should also be considered. The curren...
Roflumilast Altana Pharma [0.03%]
澳拉那制药的罗氟司特
Peter Reid
Peter Reid
Roflumilast is a specific PDE4 inhibitor being developed by Altana Pharma (formerly known as Byk Gulden) for the potential treatment of asthma and chronic obstructive pulmonary disease [312928].
Alexandre Trifilieff
Alexandre Trifilieff
ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthrit...
Anti-IgE therapy of asthma [0.03%]
哮喘的抗IgE治疗
K Fan Chung
K Fan Chung
There is a strong association between serum levels of immunoglobulin E (IgE) and asthma development. Allergen binds to IgE on basophils and mast cells, leading to cell degranulation and release of inflammatory mediators. A humanized antibod...
Gurdip Bhalay,David A Sandham
Gurdip Bhalay
The currently available therapy for asthma is highly effective and is able to control the disease in the majority of patients. There are two types of treatments for asthma: rapid relief of symptoms, used as needed and long-term control, use...
Masanori Baba
Masanori Baba
Sam Jin is investigating SJ-3366, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the potential treatment of HIV infection [302450]. As well as acting as an NNRTI, SJ-3366 also interferes with HIV-1 entry via an intermediate t...
Nesrina Imami,Gareth Hardy,Antonio Pires et al.
Nesrina Imami et al.
HIV-1-specific CD8 cytotoxic and CD4 helper T-lymphocytes, which are respectively the central effector and regulatory cells in viral infections, together with fully functional antigen-presenting cells, are essential at all stages of HIV-1 i...